Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Immune Checkpoint inhibitors (ICIs) + Tyrosine Kinase Inhibitors (TKIs) showed superior progression-free survival time and tumor response rate over TKIs alone as second-line treatment in patients with metastatic Renal cell carcinoma (RCC). However, future randomized prospective trials are necessary to validate these preliminary findings.
We conducted a Meta-analysis by gathering all relevant randomized clinical trials from sources such as the Cochrane Library, PubMed/Med, and EMBASE. Ultimately, we included three Phase III randomized clinical trials combining [Immune Check…